AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06217042
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks.
Trial: NCT06217042
Drug: gemcitabine; capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
Trial: NCT05123482
Drug: AZD8205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
Trial: NCT06313255
Drug: PegIFNα2b+probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive both PegIFNα2b and probiotics therapy
Trial: NCT06313255
Drug: Nucleoside analog
RxNorm normalized name: Nucleoside analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive nucleoside analog therapy
Trial: NCT05794581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as SC Injection
Trial: NCT06313255
Drug: Nucleoside analog+probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive both nucleoside analog and probiotics therapy
Trial: NCT05942365
Drug: ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Warfarin oral Drug midazolam oral
Trial: NCT05051436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered for 14 weeks after baseline procedures.
Trial: NCT04955236
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
Trial: NCT05019430
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined.
Trial: NCT06126510
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
Trial: NCT04028713
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
Trial: NCT05432206
Drug: Cannabis Sativa Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
Trial: NCT05432206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp virgin seed oil
Trial: NCT06535308
Drug: BnH-015B 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean / 3 on BnH-015B, 1 on placebo
Trial: NCT06535308
Drug: BnH-015B 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caucasian / 6 on BnH-015B, 2 on placebo
Trial: NCT06535308
Drug: BnH-015B 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Trial: NCT06535308
Drug: BnH-015B 40 mg (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Trial: NCT06535308
Drug: BnH-015B 80 mg (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Trial: NCT06535308
Drug: BnH-015B 80 mg (Part II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean / 9 subjects
Trial: NCT06535308
Drug: BnH-015B Placebo (Part II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean / 6 subjects
Trial: NCT05571059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo
Trial: NCT05514275
Drug: Endostatin and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
Trial: NCT04576975
Drug: Normal Saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
Trial: NCT05660356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer provided placebo
Trial: NCT04987294
Drug: ALLN-346
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
Trial: NCT04987294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Trial: NCT05486598
Drug: AL8326 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.
Trial: NCT06699680
Drug: PRX019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06699680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05655819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
Trial: NCT06349798
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
Trial: NCT05421741
Drug: Antibiotic coated intramedullary Nail
RxNorm normalized name: Fungi-Nail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube.
Trial: NCT05552625
Drug: TADIOS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
Trial: NCT05552625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
Trial: NCT05263206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection solution SC
Trial: NCT03863288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal spray liquid administration
Trial: NCT06456567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05717361
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Trial: NCT05758246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT05291091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally once per day
Trial: NCT05693935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 2 monthly injections (Period 1 only)
Trial: NCT05722522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Trial: NCT05243823
Drug: Vagifem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to local clinical practice - independent of inclusion in this study
Trial: NCT05243823
Drug: Non-Vagifem® LDVE, Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to local clinical practice - independent of inclusion in this study
Trial: NCT06247462
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
Trial: NCT05366335
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
Trial: NCT05366335
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
Trial: NCT04163328
Drug: HydroEye®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an omega-3 fatty acids supplement.
Trial: NCT05208814
Drug: TPN171H single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TPN171H taken once
Trial: NCT06338995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05972681
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine (1:200,000) injected to the vaginal laceration site.
Trial: NCT05132153
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be given by nebuliztion
Trial: NCT06780865
Drug: Placebo-controlled group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are treated with corresponding placebo
Trial: NCT02988297
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
Trial: NCT02988297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized Placebo will be administered by daily inhalation for 24 weeks.
Trial: NCT05183061
Drug: Ehedrine Norepineprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No interventions required considering that this was a retrospective study.
Trial: NCT06223711
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
Trial: NCT05045768
Drug: (Gelsectan, Devintec Sagl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
Trial: NCT05723198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06792162
Drug: Carilizumab and Apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
Trial: NCT05414422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT06435936
Drug: Single Ascending Dose of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose
Trial: NCT06261502
Drug: CBD Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
Trial: NCT06261502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
Trial: NCT05676203
Drug: Standard ADT (androgen deprivation therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed by the treating physician.
Trial: NCT04968990
Drug: DD-4A Chemotherapy Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard of care chemotherapy based on diagnosis and stage.
Trial: NCT05512403
Drug: PET/CT with 18F-DOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction
Trial: NCT06701903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet, taken once daily, sublingual administration
Trial: NCT06294912
Drug: MK-7602
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules to be administered orally.
Trial: NCT06784622
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
Trial: NCT05686408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet orally once daily for 6 weeks.
Trial: NCT04686539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oil
Trial: NCT05022303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Trial: NCT05379179
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Trial: NCT05434156
Drug: ELE-101 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELE-101 placebo matching solution for intravenous infusion
Trial: NCT05493111
Drug: 0.003% AR-15512 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via topical ocular instillation
Trial: NCT01970124
Drug: KPS-0373, Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06192693
Drug: Capsulized placebo transfer containing dilution solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Trial: NCT06005493
Drug: AZD5863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
Trial: NCT05527418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during 16 weeks.
Trial: NCT06557161
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Trial: NCT06499324
Drug: BTA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Trial: NCT06499324
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Trial: NCT05367245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only Cal-Mag but no Butyric acid
Trial: NCT05485961
Drug: CSL300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT05485961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% w/v NaCl
Trial: NCT05485961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
Trial: NCT05731947
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Trial: NCT06559345
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Trial: NCT04932395
Drug: Anshen Buxin Liuwei Pill
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 capsules/time, 2 times/day, orally.
Trial: NCT04932395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
Trial: NCT05248776
Drug: CPL207280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Trial: NCT05248776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT06782685
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m\^2, i.v.，d1
Trial: NCT06772415
Drug: GenSci122 tablet 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally Once Daily